ISBN 10: 1489539808 / ISBN 13: 9781489539809
Gebraucht / Anzahl: 0
Bei weiteren Verkäufern erhältlich
Alle  Exemplare dieses Buches anzeigen

Über dieses Buch

Leider ist dieses Exemplar nicht mehr verfügbar. Wir haben Ihnen weitere Exemplare dieses Titels unten aufgelistet.

Beschreibung:

This Book is in Good Condition. Clean Copy With Light Amount of Wear. 100% Guaranteed. Summary: Anemia is very common in patients with heart disease: about one-third of congestive heart failure (CHF) patients and 10 to 20 percent of coronary heart disease (CHD) patients are anemic, though prevalence estimates vary according to the definition used and illness burden in the population being studied. The etiology of anemia in heart disease remains incompletely understood, though there are a number of factors that likely contribute including: comorbid chronic kidney disease, blunted erythropoietin production, hemodilution, aspirin-induced gastrointestinal blood loss, the use of renin-angiotensin-aldosterone system (RAAS) blockers, cytokine-mediated inflammation (anemia of chronic disease), and gut malabsorption with consequent nutritional deficiency. Iron deficiency is also common. Cytokine mediated sequestration of iron in the reticuloendothelial system may contribute to a functional iron deficiency, while an absolute deficiency can result from decreased oral iron absorption associated with cytokine induced hepcidin synthesis. Anemia is associated with poor outcomes in patients with heart disease, but it is unclear whether anemia directly and independently contributes to these poor outcomes, or whether it simply reflects more severe underlying illness and comorbidities. Strategies to correct anemia and/ or iron deficiency have included erythropoiesis-stimulating agents, iron supplementation, and red blood cell transfusions. The purpose of this systematic review is to summarize the health outcome effects of each of these treatment strategies in adult medicine patients with heart disease. The objective of this evidence review is to evaluate the balance of benefit and harms of these treatments. We conducted a systematic review to address the following key questions: In patients with CHF or CHD, Key Question #1. What are the health outcome benefits and harms of treating anemia with ESAs? Key Question #2. What are the health outcome benefits and harms of using iron to treat iron deficiency with or without anemia? Key Question #3. What are the health outcome benefits and harms of treating anemia with red blood cell transfusions?. Buchnummer des Verkäufers

Über diesen Titel:

Bewertung (bereitgestellt von GoodReads):
0 durchschnittlich
(0 Bewertungen)

Inhaltsangabe: Anemia is very common in patients with heart disease: about one-third of congestive heart failure (CHF) patients and 10 to 20 percent of coronary heart disease (CHD) patients are anemic, though prevalence estimates vary according to the definition used and illness burden in the population being studied. The etiology of anemia in heart disease remains incompletely understood, though there are a number of factors that likely contribute including: comorbid chronic kidney disease, blunted erythropoietin production, hemodilution, aspirin-induced gastrointestinal blood loss, the use of renin-angiotensin-aldosterone system (RAAS) blockers, cytokine-mediated inflammation (anemia of chronic disease), and gut malabsorption with consequent nutritional deficiency. Iron deficiency is also common. Cytokine mediated sequestration of iron in the reticuloendothelial system may contribute to a functional iron deficiency, while an absolute deficiency can result from decreased oral iron absorption associated with cytokine induced hepcidin synthesis. Anemia is associated with poor outcomes in patients with heart disease, but it is unclear whether anemia directly and independently contributes to these poor outcomes, or whether it simply reflects more severe underlying illness and comorbidities. Strategies to correct anemia and/ or iron deficiency have included erythropoiesis-stimulating agents, iron supplementation, and red blood cell transfusions. The purpose of this systematic review is to summarize the health outcome effects of each of these treatment strategies in adult medicine patients with heart disease. The objective of this evidence review is to evaluate the balance of benefit and harms of these treatments. We conducted a systematic review to address the following key questions: In patients with CHF or CHD, Key Question #1. What are the health outcome benefits and harms of treating anemia with ESAs? Key Question #2. What are the health outcome benefits and harms of using iron to treat iron deficiency with or without anemia? Key Question #3. What are the health outcome benefits and harms of treating anemia with red blood cell transfusions?

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Bibliografische Details




Zustand: Used

Beste Suchergebnisse bei AbeBooks

1.

U. S. Department of Veterans Affairs
Verlag: Createspace
ISBN 10: 1489539808 ISBN 13: 9781489539809
Neu Paperback Anzahl: 20
Print-on-Demand
Anbieter
BuySomeBooks
(Las Vegas, NV, USA)
Bewertung
[?]

Buchbeschreibung Createspace. Paperback. Buchzustand: New. This item is printed on demand. Paperback. 84 pages. Dimensions: 11.0in. x 8.5in. x 0.2in.Anemia is very common in patients with heart disease: about one-third of congestive heart failure (CHF) patients and 10 to 20 percent of coronary heart disease (CHD) patients are anemic, though prevalence estimates vary according to the definition used and illness burden in the population being studied. The etiology of anemia in heart disease remains incompletely understood, though there are a number of factors that likely contribute including: comorbid chronic kidney disease, blunted erythropoietin production, hemodilution, aspirin-induced gastrointestinal blood loss, the use of renin-angiotensin-aldosterone system (RAAS) blockers, cytokine-mediated inflammation (anemia of chronic disease), and gut malabsorption with consequent nutritional deficiency. Iron deficiency is also common. Cytokine mediated sequestration of iron in the reticuloendothelial system may contribute to a functional iron deficiency, while an absolute deficiency can result from decreased oral iron absorption associated with cytokine induced hepcidin synthesis. Anemia is associated with poor outcomes in patients with heart disease, but it is unclear whether anemia directly and independently contributes to these poor outcomes, or whether it simply reflects more severe underlying illness and comorbidities. Strategies to correct anemia and or iron deficiency have included erythropoiesis-stimulating agents, iron supplementation, and red blood cell transfusions. The purpose of this systematic review is to summarize the health outcome effects of each of these treatment strategies in adult medicine patients with heart disease. The objective of this evidence review is to evaluate the balance of benefit and harms of these treatments. We conducted a systematic review to address the following key questions: In patients with CHF or CHD, Key Question 1. What are the health outcome benefits and harms of treating anemia with ESAs Key Question 2. What are the health outcome benefits and harms of using iron to treat iron deficiency with or without anemia Key Question 3. What are the health outcome benefits and harms of treating anemia with red blood cell transfusions This item ships from La Vergne,TN. Paperback. Buchnummer des Verkäufers 9781489539809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 22,06
Währung umrechnen

In den Warenkorb

Versand: EUR 3,69
Innerhalb USA
Versandziele, Kosten & Dauer

2.

U S Department of Veterans Affairs, Health Services Research Deve Service
Verlag: Createspace, United States (2013)
ISBN 10: 1489539808 ISBN 13: 9781489539809
Neu Paperback Anzahl: 10
Print-on-Demand
Anbieter
The Book Depository US
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung Createspace, United States, 2013. Paperback. Buchzustand: New. 279 x 216 mm. Language: English . Brand New Book ***** Print on Demand *****. Anemia is very common in patients with heart disease: about one-third of congestive heart failure (CHF) patients and 10 to 20 percent of coronary heart disease (CHD) patients are anemic, though prevalence estimates vary according to the definition used and illness burden in the population being studied. The etiology of anemia in heart disease remains incompletely understood, though there are a number of factors that likely contribute including: comorbid chronic kidney disease, blunted erythropoietin production, hemodilution, aspirin-induced gastrointestinal blood loss, the use of renin-angiotensin-aldosterone system (RAAS) blockers, cytokine-mediated inflammation (anemia of chronic disease), and gut malabsorption with consequent nutritional deficiency. Iron deficiency is also common. Cytokine mediated sequestration of iron in the reticuloendothelial system may contribute to a functional iron deficiency, while an absolute deficiency can result from decreased oral iron absorption associated with cytokine induced hepcidin synthesis. Anemia is associated with poor outcomes in patients with heart disease, but it is unclear whether anemia directly and independently contributes to these poor outcomes, or whether it simply reflects more severe underlying illness and comorbidities. Strategies to correct anemia and/ or iron deficiency have included erythropoiesis-stimulating agents, iron supplementation, and red blood cell transfusions. The purpose of this systematic review is to summarize the health outcome effects of each of these treatment strategies in adult medicine patients with heart disease. The objective of this evidence review is to evaluate the balance of benefit and harms of these treatments. We conducted a systematic review to address the following key questions: In patients with CHF or CHD, Key Question #1. What are the health outcome benefits and harms of treating anemia with ESAs? Key Question #2. What are the health outcome benefits and harms of using iron to treat iron deficiency with or without anemia? Key Question #3. What are the health outcome benefits and harms of treating anemia with red blood cell transfusions?. Buchnummer des Verkäufers APC9781489539809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 45,87
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

3.

U S Department of Veterans Affairs, Health Services Research Deve Service
Verlag: Createspace, United States (2013)
ISBN 10: 1489539808 ISBN 13: 9781489539809
Neu Paperback Anzahl: 10
Print-on-Demand
Anbieter
The Book Depository
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung Createspace, United States, 2013. Paperback. Buchzustand: New. 279 x 216 mm. Language: English . Brand New Book ***** Print on Demand *****.Anemia is very common in patients with heart disease: about one-third of congestive heart failure (CHF) patients and 10 to 20 percent of coronary heart disease (CHD) patients are anemic, though prevalence estimates vary according to the definition used and illness burden in the population being studied. The etiology of anemia in heart disease remains incompletely understood, though there are a number of factors that likely contribute including: comorbid chronic kidney disease, blunted erythropoietin production, hemodilution, aspirin-induced gastrointestinal blood loss, the use of renin-angiotensin-aldosterone system (RAAS) blockers, cytokine-mediated inflammation (anemia of chronic disease), and gut malabsorption with consequent nutritional deficiency. Iron deficiency is also common. Cytokine mediated sequestration of iron in the reticuloendothelial system may contribute to a functional iron deficiency, while an absolute deficiency can result from decreased oral iron absorption associated with cytokine induced hepcidin synthesis. Anemia is associated with poor outcomes in patients with heart disease, but it is unclear whether anemia directly and independently contributes to these poor outcomes, or whether it simply reflects more severe underlying illness and comorbidities. Strategies to correct anemia and/ or iron deficiency have included erythropoiesis-stimulating agents, iron supplementation, and red blood cell transfusions. The purpose of this systematic review is to summarize the health outcome effects of each of these treatment strategies in adult medicine patients with heart disease. The objective of this evidence review is to evaluate the balance of benefit and harms of these treatments. We conducted a systematic review to address the following key questions: In patients with CHF or CHD, Key Question #1. What are the health outcome benefits and harms of treating anemia with ESAs? Key Question #2. What are the health outcome benefits and harms of using iron to treat iron deficiency with or without anemia? Key Question #3. What are the health outcome benefits and harms of treating anemia with red blood cell transfusions?. Buchnummer des Verkäufers APC9781489539809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 47,12
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer